A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone in Patients with Metastatic Prostate Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516661-37-00

Acronym

ARV-110-mCRPC-103

Enrollment

Registered

2024-10-29

Start date

2022-07-27

Completion date

2024-12-10

Last updated

2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Prostate Cancer

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026